Friday, after a week dominated by small-cap offerings like Virios Therapeutics, GoodRx announced they too would try to go public. And although they don’t quite have Pablo Legorreta-like ambitions, the consumer prescription drug platform and drug price watchdog is reportedly still shooting well above Moderna: $750 million.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,